MedPath

Leishen Energy

🇬🇧United Kingdom
Ownership
-
Established
1895-01-01
Employees
173
Market Cap
-
Website
https://www.lse.ac.uk/
Introduction

Leishen Energy Holding Co., Ltd. engages in the provision of clean-energy equipment and integrated solutions to the oil and gas industry. It operates through the following business segments; Clean-Energy Equipment; Oil and Gas Engineering Technical Services; New Energy Production and Operation; Digitalization and Integration Equipment; The Clean-Energy Equipment segment supplies wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment and polymer flexible composite pipes. The Oil and Gas Engineering Technical Services segment provides customers with a products and technical solutions for oil and gas production. The New Energy Production and Operation segment focuses on the production, storage and transportation of natural gas, traditional fuels, development of distributed energy, and the planning and operation of new energy and new energy industries. The Digitalization and Integration Equipment segment designed to provide informatization solutions for industrial intelligence, mobility, industrial interconnection and big data trends. The company was founded by Hongqi Li in 2007 and is headquartered in Beijing, China.

Clinical Trials

12

Active:1
Completed:8

Trial Phases

1 Phases

Not Applicable:10

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Not Applicable
10 (100.0%)

Communicating Multiple Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Not Applicable
Not yet recruiting
Conditions
Cancer
First Posted Date
2025-08-07
Last Posted Date
2025-08-07
Lead Sponsor
London School of Economics and Political Science
Target Recruit Count
3000
Registration Number
NCT07110597

Effect of Communicating Structured Benefit and Harm Information in European Patient Leaflets on Individuals' Expectations About Medicines

Not Applicable
Not yet recruiting
Conditions
Cancer
First Posted Date
2025-07-11
Last Posted Date
2025-07-11
Lead Sponsor
London School of Economics and Political Science
Target Recruit Count
2100
Registration Number
NCT07061197

Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Not Applicable
Recruiting
Conditions
Cancer
First Posted Date
2025-05-30
Last Posted Date
2025-05-30
Lead Sponsor
London School of Economics and Political Science
Target Recruit Count
3000
Registration Number
NCT06997185
Locations
🇺🇸

Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States

Evaluating the Impact of a Digital Psychosocial Tool (Wysa) on Life Skills and Well-being of College Students in India

Not Applicable
Completed
Conditions
Wellbeing
Resilience
Self Efficacy
Life Skills
Problem Solving
First Posted Date
2025-01-30
Last Posted Date
2025-06-25
Lead Sponsor
London School of Economics and Political Science
Target Recruit Count
152
Registration Number
NCT06801093
Locations
🇮🇳

Indian Institute of Technology, Gandhinagar (IIT-Gandhinagar), Palaj, Gujarat, India

Evaluation of a Comprehensive School Health Programme in Zambia

Not Applicable
Active, not recruiting
Conditions
Malaria
Diarrhea
Anemia
Cough
Helminth Infection
UTI
Schistosomiasis
Skin Rash
First Posted Date
2024-08-19
Last Posted Date
2024-08-19
Lead Sponsor
London School of Economics and Political Science
Target Recruit Count
28700
Registration Number
NCT06560853
Locations
🇿🇲

Chingola District Education Board, Chingola, Copperbelt, Zambia

🇿🇲

Luanshya District Education Board, Luanshya, Copperbelt, Zambia

🇿🇲

Masaiti District Education Board, Masaiti, Copperbelt, Zambia

and more 3 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

Medicare's First Drug Price Negotiations Yield Mixed Results: U.S. Prices Still Exceed International Levels

Medicare's first round of drug price negotiations achieved reductions ranging from 8% to 42% across ten medications, with sitagliptin showing the most significant price decrease.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.